NCI-H358-KRAS-G12C-R68S-KI Cell Line

KRAS-G12C-R68S is a rare double mutation in the KRAS oncogene, combining the well-characterized G12C mutation with the less studied R68S variant. The G12C mutation, commonly found in non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer, confers constitutive activation of KRAS by impairing GTP hydrolysis, leading to sustained oncogenic signaling. The R68S mutation, located in the switch II region of KRAS, may further modulate protein dynamics and interactions with downstream effectors such as RAF and PI3K. Preliminary studies suggest that the R68S mutation could alter the conformational stability of KRAS, potentially influencing its responsiveness to targeted therapies, including G12C-specific inhibitors like sotorasib and adagrasib. However, the functional and clinical implications of the double mutation remain poorly understood due to its rarity and the complexity of KRAS signaling networks. Further research is needed to elucidate the mechanistic interplay between G12C and R68S, their combined impact on tumorigenesis, and their potential as therapeutic targets. Understanding this dual mutation could provide insights into resistance mechanisms and guide the development of more effective KRAS-targeted therapies.